The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.

Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.

How can you participate in a clinical trial at Cabrini

The Szalmuk Family Department of Medical Oncology currently has more than 100 active clinical trials covering many different cancer streams. If you are interested in participating in a trial, please speak to your treating oncologist first. Your oncologist will provide you with general information on clinical trials and also discuss programs that may be relevant to you.

All patients with private health insurance can participate, and in some trials public patients are also eligible.

You can also contact our trial department directly on (03) 9508 3421 or by emailing to lihoonlai@cabrini.com.au with your enquiry. Support groups or consumer health organisations with an interest in a particular disease or condition may also have information on relevant trials, or be able to provide contact information for other patients who have been involved in trials.

 

Phase I

Protocol Number - ALE17001/FN-1501-UP1

A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics (PK) And Anti-Tumor Activity Of FN-1501 Monotherapy In Patients With Advanced Solid Tumors

Download more information >

Protocol Number - FPT155-001

Phase 1A/1B Study Of FPT155 In Patients With Advanced Solid Tumours

Download more information >

Protocol Number - CO41012 (IPATunity150)

A Phase IB/III Study Of Ipatasertib Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Hormone Receptor Positive And Her2 Negative Locally Advanced Unresectable Or Metastatic Breast Cancer

Download more information >

Protocol Number - CN1-101

A Phase I, Open Label, Multi-Centre, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumours or B-cell Lymphoma

Download more information >

Protocol Number - ADG116-1003

A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors

Download more information >

Protocol Number - 1336-0011

An Open Label Phase Ib Dose Finding Study Of BI 836880 In Combination With BI 754091 To Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy In Patients With Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer And In Other Solid Tumors

Download more information >

Protocol Number - ZN-c3-002

A Phase 1b Study of ZN-c3 In Combination With Chemotherapy In Patients With Platinum-Resistant Ovarian, Peritoneal Or Fallopian Tube Cancer

Download more information >

Protocol Number - IMU 201 101

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer

Download more information >

Protocol Number - GQ1001X2101

A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of GQ1001, a HER2 Antibody-Drug Conjugate, in Patients with HER2-Positive Advanced Solid Tumors

Download more information >

Protocol Number - D1553-101

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid Tumours with KRasG12C Mutation

Download more information >

Protocol Number - KFCS001

A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients with Advanced Solid Tumors

Download more information >

Protocol Number - ADG126-1001

First-in-human (FIH), Open-Label, Phase I Dose Escalation Study of ADG126 in Patients with Advanced Malignancies.

Download more information >

Melanoma

Protocol Number - CA209-7CK

A prospective observational study in patients receiving adjuvant nivolumab therapy for resected
melanoma in Australia

Download more information >

Protocol Number - CA209-76K

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma

Download more information >

Lung

Protocol Number - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Download more information >

Protocol Number - 1336-0011

An Open Label Phase Ib Dose Finding Study Of BI 836880 In Combination With BI 754091 To Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy In Patients With Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer And In Other Solid Tumors

Download more information >

Protocol Number - IMU 201 101

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer

Download more information >

Protocol Number - 73841937NSC3003 (MARIPOSA)

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Download more information >

Protocol Number - 61186372NSC3001 (PAPILLON)

A Randomized, Open-label Phase C81tin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON)

Download more information >

Haematological / Blood cancers

Protocol Number - ACE-536-MDS-002

A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naive Subjects Who Require Red Blood Cell Transfusions

Download more information >

Protocol Number - CN1-101

A Phase I, Open Label, Multi-Centre, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumours or B-cell Lymphoma

Download more information >

Protocol Number - GCT3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma

Download more information >

Protocol Number - 5F9009-3

A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome

Download more information >

Protocol Number - DREAMM-8

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (GSK2857916+Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma

Download more information >

Colorectal

Protocol Number - WEHI-ctDNA11

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study

Download more information >

Protocol Number - AveRec Trial

Phase II Trial PD-L1/PD-1 Blockade Avelumab (MSB0010718C) With Chemoradiotherapy For Locally Advanced ResectableT3b-4/N1-2 Rectal Cancer

Download more information >

Genitourinary

Protocol Number - CA209914

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Download more information >

Protocol Number - 64091742PCR3001

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For Treatment Of Subjects With Metastatic Prostate Cancer

Download more information >

Protocol Number - CA209-7DX

A Phase 3 Randomized, Double-Blind Study Of Nivolumab Or Placebo In Combination With Docetaxel, In Men With Metastatic Castration-resistant Prostate Cancer

Download more information >

Protocol Number - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Download more information >

Protocol Number - 89Zr-TLX250-003

A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses

Download more information >

Breast Cancer

Protocol Number - CO41012 (IPATunity150)

A Phase IB/III Study Of Ipatasertib Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Hormone Receptor Positive And Her2 Negative Locally Advanced Unresectable Or Metastatic Breast Cancer

Download more information >

Gynaecological

Protocol Number - ZN-c3-002

A Phase 1b Study of ZN-c3 In Combination With Chemotherapy In Patients With Platinum-Resistant Ovarian, Peritoneal Or Fallopian Tube Cancer

Download more information >

Protocol Number - IMGN853-416

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Download more information >

Gastrointestinal

Protocol Number - SGNLVA-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Download more information >

Protocol Number - 1336-0011

An Open Label Phase Ib Dose Finding Study Of BI 836880 In Combination With BI 754091 To Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy In Patients With Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer And In Other Solid Tumors

Download more information >

Pancreatic

Protocol Number - ct-DNA-09

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (DYNAMIC-Pancreas)

Download more information >

COVID-19

Protocol Number - COVID-19 In Cancer Patients

A Multi-Centre National study of COVID-19 Infection in Cancer Patients

Download more information >

There are no results to your search.

The keyword you entered is too short. Please use at least three characters.